SCHEMBL25914397

SCHEMBL25914397

O=S(=O)(O)Cc1noc(-c2ccc(Br)cc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 4/20 0.48
HDAC1 Q13547 3/20 0.48
HDAC8 Q9BY41 2/20 0.48
SMPD1 P17405 1/20 0.48
NOTUM Q6P988 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
NR1H4 Q96RI1 1/20 0.45
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PPARG P37231 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25914392 0.86 NOTUM (0.65) SMPD1NOTUMMEN1LMNAPOLB
SCHEMBL25914401 0.75 NPC1 (0.54) NOTUMMEN1LMNAPOLBKMT2A
SCHEMBL15742312 0.75 NOTUM (0.53) HDAC6HDAC1HDAC8SMPD1NOTUM
SCHEMBL4668238 0.75 RAB9A (0.54) HDAC6HDAC1HDAC8SMPD1NOTUM
SCHEMBL25914384 0.74 SIRT2 (0.56) NOTUMMEN1LMNAKMT2ANR1H4
SCHEMBL29254346 0.73 SIRT2 (0.55) NOTUMMEN1LMNAKMT2ANR1H4
SCHEMBL1272319 0.70 NOTUM (0.58) HDAC6HDAC1HDAC8NOTUMMEN1
SCHEMBL1272321 0.70 NOTUM (0.58) HDAC6HDAC1HDAC8NOTUMMEN1
SCHEMBL24988600 0.70 TARBP2 (0.52) HDAC6HDAC1HDAC8SMPD1NOTUM
SCHEMBL8404853 0.70 MEN1 (0.47) HDAC6HDAC1NOTUMMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-20230265061-A1 OXADIAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2023-08-24 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed
US-11718592-B2 Oxadiazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718592-B2 Oxadiazole derivative OXA1L, SCN1A, CACNA1A HDAC6 66/4885HDAC1 10/4885HDAC8 460/4885
US-20230265061-A1 OXADIAZOLE DERIVATIVE OXA1L, SCN1A, CACNA1A HDAC6 66/4885HDAC1 10/4885HDAC8 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.